Reply—Examining pregnancy outcomes in alcohol-associated hepatitis: A call for further research

We thank Dr El-Kassas and colleagues for their thoughtful comments on our recent publication exploring pregnancy outcomes in women with alcohol-associated hepatitis (AH).1 We feel that the authors both recognized the novelty of our study and raised valid points of concern regarding study design. Among these, there are 2 points we would like to address: First, we acknowledge the concerns regarding the use of ICD-10 codes to identify patients with AH, given the variability in diagnostic patterns. Our colleagues suggested using validated algorithms and/or incorporating laboratory data to improve patient identification—citing a recent study that validated coding algorithms for cirrhosis—not AH.2 Looking closer, the supplemental materials for the referenced study suggest that the AH ICD-10 code (K70.1) alone might have higher specificity for identifying AH compared to the ICD-10 code plus laboratory data. Although there is an opportunity to learn more through large-scale chart reviews and prospective data collection, we believe that our strategy minimized the risk of falsely including women without AH and that our findings accurately represent the target population. Nevertheless, we agree that future studies should focus on developing both sensitive and specific coding algorithms to identify AH for database research. Second, the authors noted the absence of detailed information on alcohol consumption patterns, suggesting these data are needed to determine AH severity. Although we agree that patterns of alcohol intake influence the risk of AH development and recurrence, there are several modifiers of this relationship, such as genetic predisposition, body composition, and environmental factors.3 We chose to use biochemical markers as objective measures of AH severity and recurrent AH as a surrogate for high-risk drinking behaviors. As the authors point out, we observed fewer pregnancies among women with higher bilirubin levels and more adverse pregnancy outcomes in women with recurrent AH. While understanding alcohol consumption patterns would further characterize this population and inform future interventions, our findings sufficiently demonstrate that both the severity of liver dysfunction and high-risk alcohol use influence pregnancy outcomes. Finally, we are very encouraged by the suggestions for future research, including biomarker identification and evaluation of medication-assisted therapies, and investigation into racial and ethnic disparities. Given the increasing incidence of AH in women of reproductive age, further research will be essential to inform management strategies and improve clinical outcomes. We hope our use of large-scale, real-world data will inspire such investigations. We thank Dr El-Kassas and colleagues again for their in-depth analysis of our article and the opportunity to advance the conversation around this important clinical issue.

Authors

Institutions

Publication Details

Journal
Hepatology Communications
Published
2025-06-19
DOI
https://doi.org/10.1097/hc9.0000000000000724
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Reply—Examining pregnancy outcomes in alcohol-associated hepatitis: A call for further research

Deepika Devuni, Katherine M. Cooper, Ami Patel
Hepatology Communications
Liver Disease Diagnosis and Treatment
article

Reply—Examining pregnancy outcomes in alcohol-associated hepatitis: A call for further research

Deepika Devuni, Katherine M. Cooper, Ami Patel
article en

Abstract

We thank Dr El-Kassas and colleagues for their thoughtful comments on our recent publication exploring pregnancy outcomes in women with alcohol-associated hepatitis (AH).1 We feel that the authors both recognized the novelty of our study and raised valid points of concern regarding study design. Among these, there are 2 points we would like to address: First, we acknowledge the concerns regarding the use of ICD-10 codes to identify patients with AH, given the variability in diagnostic patterns. Our colleagues suggested using validated algorithms and/or incorporating laboratory data to improve patient identification—citing a recent study that validated coding algorithms for cirrhosis—not AH.2 Looking closer, the supplemental materials for the referenced study suggest that the AH ICD-10 code (K70.1) alone might have higher specificity for identifying AH compared to the ICD-10 code plus laboratory data. Although there is an opportunity to learn more through large-scale chart reviews and prospective data collection, we believe that our strategy minimized the risk of falsely including women without AH and that our findings accurately represent the target population. Nevertheless, we agree that future studies should focus on developing both sensitive and specific coding algorithms to identify AH for database research. Second, the authors noted the absence of detailed information on alcohol consumption patterns, suggesting these data are needed to determine AH severity. Although we agree that patterns of alcohol intake influence the risk of AH development and recurrence, there are several modifiers of this relationship, such as genetic predisposition, body composition, and environmental factors.3 We chose to use biochemical markers as objective measures of AH severity and recurrent AH as a surrogate for high-risk drinking behaviors. As the authors point out, we observed fewer pregnancies among women with higher bilirubin levels and more adverse pregnancy outcomes in women with recurrent AH. While understanding alcohol consumption patterns would further characterize this population and inform future interventions, our findings sufficiently demonstrate that both the severity of liver dysfunction and high-risk alcohol use influence pregnancy outcomes. Finally, we are very encouraged by the suggestions for future research, including biomarker identification and evaluation of medication-assisted therapies, and investigation into racial and ethnic disparities. Given the increasing incidence of AH in women of reproductive age, further research will be essential to inform management strategies and improve clinical outcomes. We hope our use of large-scale, real-world data will inspire such investigations. We thank Dr El-Kassas and colleagues again for their in-depth analysis of our article and the opportunity to advance the conversation around this important clinical issue.

Hepatology CommunicationsVol. 9(7)
University of Massachusetts Chan Medical School (US)
Openalex Percentile: Top 80%
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.